Faculty of Sexual and Reproductive Healthcare, Royal College of the Obstetricians and Gynaecologists (UK), 22 March 2023 FSRH response to new study on use of combined and progestogen-only hormonal contraception and breast cancer risk: A new observational study by Fitzpatrick, et al., published in PLOS Medicine investigated the association between current or recent use of combined oral and...
University of Queensland, March 2021 A common intrauterine device (IUD) could help preserve fertility and reduce the need for hysterectomies for women suffering endometrial cancer, according to University of Queensland research. UQ’s Professor Andreas Obermair, from the Queensland Centre for Gynaecological Cancer Research, said his team had just completed the feMMe study – a phase II randomised...
nam/aidsmap, 7 September 2020 A study in which 24 trans women and 24 trans men who were taking gender-affirming hormone therapy were directly observed to take a daily dose of the standard formulation of the HIV prevention medication PrEP found that the levels of the two PrEP drugs tenofovir and emtricitabine were similar to the levels seen in similar cis men and women, and were all above levels...
The Guardian, Fri 3 May 2019 09.01 AESTLast modified on Fri 3 May 2019 09.50 AEST Women on the combined pill appear to be less likely to tear a key ligament in their knee, research suggests. Tears to the ACL are known to be more common in women than men, with previous research suggesting fluctuations in hormones during the menstrual cycle, including oestrogen, might play a role by increasing the...
SHINE SA, issued 13th December 2017 SHINE SA believes everyone should have access to contraceptive choices, and that decisions about contraception are best made in conjunction with a healthcare professional. Cyproterone acetate pills, commonly known as Diane-35 appear to be associated with a higher risk of deep venous thrombosis (DVT) than levonorgestrel (LNG) containing pills, although the...
SHine SA, October 2016 SHine SA and Family Planning Alliance Australia put in submissions to the TGA for the rescheduling of ulipristal acetate (EllaOne®), a new emergency contraceptive pill in Australia. The rescheduling is from prescription-only to Schedule 3 (available in pharmacies with a pharmacy consultation). This has now been approved, to take place from February 2017. This is an...